Drug profile · INN
methylprednisolone
ADVANTAN
methylprednisolone (ADVANTAN) is a glucocorticoid receptor agonist. Associated with Pfizer Australia Pty Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.
Drug details — methylprednisolone
- US status
- approved
- Class
- —
- Route
- OPHTHALMIC
- Patents
- 0
- Programs
- 52
- Data quality
- 0.89
Quick answer
methylprednisolone (ADVANTAN) is a glucocorticoid receptor agonist. Associated with Pfizer Australia Pty Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.
Key facts
Mechanism of action
Glucocorticoid receptor agonist
Primary target: Glucocorticoid receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is methylprednisolone?
methylprednisolone (ADVANTAN) is a glucocorticoid receptor agonist. Associated with Pfizer Australia Pty Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.
What is the brand name for methylprednisolone?
ADVANTAN is a marketed brand name for methylprednisolone. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of methylprednisolone?
methylprednisolone has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.